Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 14.5% on Tuesday . The stock traded as low as C$0.27 and last traded at C$0.27. 438,482 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Price Performance
The firm has a market capitalization of C$23.09 million, a PE ratio of -13.25 and a beta of 0.20. The business’s 50 day moving average is C$0.11 and its two-hundred day moving average is C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What is Forex and How Does it Work?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- How to Effectively Use the MarketBeat Ratings Screener
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- CD Calculator: Certificate of Deposit Calculator
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
